Tuning of antibacterial activity of a cyclopropyl fluoroquinolone by variation of the substituent at position C-8

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 12, 2011, Pages 2801-2808

  Wetzstein, H G ^a   Hallenbach, W ^b  

^a BAYER AG   (Germany)

^b BAYER CROPSCIENCE AG   (Germany)

Author keywords

Ciprofloxacin; Enrofloxacin; Mutant prevention concentrations; Pradofloxacin; Structure activity relationships

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; BAY Y 3114; CIPROFLOXACIN; ENROFLOXACIN; HALOGEN; HYDROGEN; PIPERIDINE DERIVATIVE; PRADOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; SUBSTITUTION REACTION; WILD TYPE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 81855190659     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr372     Document Type: Article

References (37)

1. Spindel ME, Veir JK, Radecki SV et al. Evaluation of pradofloxacin for the treatment of feline rhinitis. J Feline Med Surg 2008; 10: 472-9.
2. Restrepo C, Ihrke PJ, White SD et al. Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma. J Am Anim Hosp Assoc 2010; 46: 301-11.
3. Zhao X, Xu C, Domagala J et al. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 1997; 94: 13991-6.
4. Dong J, Zhao X, Domagala J et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1756-8.
5. Zhao X, Drlica K. A unified anti-mutant dosing strategy. J Antimicrob Chemother 2008; 62: 434-6.
6. Sieradzki K, Roberts RB, Haber SW et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-23.
7. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33 Suppl 3: 147-56.
8. Pourbakhsh SA, Boulianne M, Martineau-Doizé B et al. Dynamics of Escherichia coli infection in experimentally inoculated chickens. Avian Dis 1997; 41: 221-33.
9. Croisier D, Etienne M, Bergoin E et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 2004; 48: 1699-707.
10. Firsov AA, Vostrov SN, Lubenko IY et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 43: 2000-4.
11. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44: 681-8.
12. Croisier D, Etienne M, Piroth L et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 2004; 54: 640-7.
13. Etienne M, Croisier D, Charles P-E et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 2004; 190: 1472-5.
14. Cui J, Liu Y, Wang R et al. The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 2006; 194: 1601-8.
15. Almeida D, Nuermberger E, Tyagi S et al. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 2007; 51: 4261-6.
16. Drlica K, Malik M, Kerns RJ et al. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008; 52: 385-92.
17. Drlica K, Hiasa H, Kerns R et al. Quinolones: action and resistance updated. Curr Top Med Chem 2009; 9: 981-98.
18. Wetzstein H-G. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob Agents Chemother 2005; 49: 4166-73.
19. Petersen U. Quinolone antibiotics: the development of moxifloxacin. In: Fischer J, Ganellin CR, eds. Analogue-based Drug Discovery. Weinheim: Wiley-VCH, 2006; 315-70.
20. Karl W, Schneider J, Wetzstein H-G. Outlines of an "exploding" network of metabolites generated from the fluoroquinolone enrofloxacin by the brown rot fungus Gloeophyllum striatum. Appl Microbiol Biotechnol 2006; 71: 101-13.
21. Wetzstein H-G, Schneider J, Karl W. Comparative biotransformation of fluoroquinolone antibiotics in matrices of agricultural relevance. In: Henderson KL, Coats JR, eds. Veterinary Pharmaceuticals in the Environment. ACS Symposium Series Volume 1018. Washington, DC: American Chemical Society, 2009; 67-91.
22. Wetzstein H-G, Schneider J, Karl W. Metabolite proving fungal degradation of the aromatic core of a fluoroquinolone. In: Abstracts of the 111th General Meeting, New Orleans LA, 2011. Abstract 2773. American Society for Microbiology, Washington, DC, USA.
23. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically- Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
24. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706.
25. Laponogov I, Pan X-S, Veselkov DA et al. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS ONE 2010; 5: e11338.
26. Wohlkonig A, Chan PF, Fosberry AP et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 2010; 17: 1152-3.
27. Malik M, Marks KR, Mustaev A et al. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother 2011; 55: 2335-43.
28. Sindelar G, Zhao X, Liew A et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000; 44: 3337-43.
29. Ferguson J. Phototoxicity due to fluoroquinolones. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents, 3rd edn. Washington, DC: ASM Press, 2003; 451-60.
30. Domagala JM, Hagen SE. Structure-activity relationships of the quinolone antibacterials in the new millennium: some things change and some do not. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents, 3rd edn. Washington, DC: ASM Press, 2003; 3-18.
31. Fraatz K, Krebber R, Edingloh M et al. Oral bioavailability of pradofloxacin tablets and renal drug excretion in dogs. J Vet Pharmacol Therap 2003; 26 Suppl 1: 88-9.
32. Fraatz K. Serum pharmacokinetics of pradofloxacin after oral administration to cats. J Vet Pharmacol Therap 2006; 29 Suppl 1: 266.
33. Mitcher LA, Ma Z. Structure-activity relationships of quinolones. In: Ronald AR, Low DE, eds. Fluoroquinolone Antibiotics. Basel: Birkhäuser, 2003; 11-48.
34. Olofsson SK, Marcusson LL, Komp Lindgren P et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. Antimicrob Agents Chemother 2006; 57: 1116-21.
35. Liang B, Bai N, Cai Y et al. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 2409-12.
36. European Medicines Agency. Veraflox: EPAR-Product Information. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000159/WC500109014.pdf (26 July 2011, date last accessed).
37. Messias A, Gekeler F, Wegener A et al. Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. Doc Ophthalmol 2008; 116: 177-91.